Genentech and Roche Unveil Alzheimer’s Data at AAIC 2026 — Genentech, Inc.

Event summary

Genentech and Roche will present 18 oral and poster presentations at AAIC 2026 in London, highlighting advancements in Alzheimer’s disease diagnostics and therapeutics.
Key focus areas include trontinemab, a bispecific amyloid-beta targeting antibody, and the Elecsys pTau217 blood test for Alzheimer’s diagnosis.
New data on long-term safety, amyloid removal, and biomarker results from the Phase Ib/IIa Brainshuttle AD study will be shared.
Roche’s Elecsys pTau217 blood test recently received CE mark certification for both primary and secondary care settings.

The big picture

Genentech and Roche are advancing their integrated pharmaceutical and diagnostics portfolio to tackle Alzheimer’s disease at multiple stages. The focus on early detection and intervention aligns with broader industry trends towards personalized medicine and the need for scalable diagnostic solutions. The strategic combination of innovative therapeutics like trontinemab with advanced blood-based diagnostics aims to transform the landscape of Alzheimer’s care.

What we're watching

Therapeutic Efficacy: How the long-term safety and amyloid removal data from trontinemab will impact its Phase III trials in early symptomatic Alzheimer’s disease.
Diagnostic Adoption: The pace at which Roche’s Elecsys pTau217 blood test is integrated into primary and secondary care settings following its CE mark certification.
Preclinical Intervention: Whether the PrevenTRON Phase III study design for cognitively unimpaired individuals can successfully identify high-risk participants using Roche’s Elecsys pTau217 blood test.